Table 2.

Summary of on-study AEs

Adverse events, N (%)Grade 1Grade 2Total
Injection site reaction17 (77.3)1 (4.5)18 (81.8)
Fatigue13 (59.1)1 (4.5)14 (63.6)
Bone pain5 (22.7)1 (4.5)6 (27.3)
Headache3 (13.6)0 (0.0)3 (13.6)
Back pain2 (9.1)0 (0.0)2 (9.1)
Extremity pain2 (9.1)0 (0.0)2 (9.1)
Muscle pain1 (4.5)1 (4.5)2 (9.1)
Diarrhea1 (4.5)0 (0.0)1 (4.5)
Abdominal pain1 (4.5)0 (0.0)1 (4.5)
Fever (non-neutropenic)1 (4.5)0 (0.0)1 (4.5)
Chills1 (4.5)0 (0.0)1 (4.5)
Diaphoresis1 (4.5)0 (0.0)1 (4.5)
Rash1 (4.5)0 (0.0)1 (4.5)
Chest pain1 (4.5)0 (0.0)1 (4.5)
Joint pain1 (4.5)0 (0.0)1 (4.5)
Pruritus1 (4.5)0 (0.0)1 (4.5)
Urinary frequency1 (4.5)0 (0.0)1 (4.5)
Urinary incontinence1 (4.5)0 (0.0)1 (4.5)
Dehydration1 (4.5)0 (0.0)1 (4.5)
Hoarseness1 (4.5)0 (0.0)1 (4.5)
  • NOTE: Patients could have had more than one AE. No grade ≥3 AEs were observed.